References of "Journal of Hypertension"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailReference values of central blood pressure and pulse wave velocity in relations with 24 hours ambulatory blood pressure monitoring in Belgian normotensive young subjects
Saint-Remy, Annie ULg; Krzesinski, Jean-Marie ULg

in Journal of Hypertension (2010), 28

The present study aimed to define reference values of central blood pressure (cBP) and Pulse Wave Velocity (PWV) together with 24H APPM in healththy normotensive young adults before starting a follow-up ... [more ▼]

The present study aimed to define reference values of central blood pressure (cBP) and Pulse Wave Velocity (PWV) together with 24H APPM in healththy normotensive young adults before starting a follow-up of their CV profile modifications over time. [less ▲]

Detailed reference viewed: 58 (4 ULg)
Full Text
Peer Reviewed
See detailEffect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
MacDonald, Thomas M; Reginster, Jean-Yves ULg; Littlejohn, Thomas W et al

in Journal of Hypertension (2008), 26(8), 1695-702

OBJECTIVES: Nonsteroidal anti-inflammatory drugs vary in their impact on blood pressure and the effect of lumiracoxib 100 mg once daily has not been studied previously. To examine whether lumiracoxib 100 ... [more ▼]

OBJECTIVES: Nonsteroidal anti-inflammatory drugs vary in their impact on blood pressure and the effect of lumiracoxib 100 mg once daily has not been studied previously. To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries. METHODS: Hypertensive osteoarthritis patients of 50 years at least whose office blood pressure was less than 140/90 mmHg on stable antihypertensive treatment were randomized to lumiracoxib (n = 394) 100 mg once daily or ibuprofen 600 mg three times daily (n = 393) and 24-h ambulatory blood pressure monitoring was performed at baseline and end of study. The primary outcome measure was a comparison of the change in 24-h mean systolic ambulatory blood pressure from baseline to week 4. Secondary analyses included other blood pressure-related endpoints and efficacy (pain) measurements. RESULTS: Compared with baseline, the 24-h mean systolic ambulatory blood pressure (least square mean) decreased in lumiracoxib-treated patients (-2.7 mmHg) and increased in ibuprofen-treated patients (+2.2 mmHg) at 4 weeks, estimated difference -5.0 mmHg (95% confidence interval -6.1 to -3.8) in favour of lumiracoxib. The 24-h mean diastolic ambulatory blood pressure changes were -1.5 mmHg (lumiracoxib), +0.5 mmHg (ibuprofen), difference -2.0 mmHg (95% confidence interval -2.7 to -1.3). Efficacy results were comparable. CONCLUSIONS: Treatment with lumiracoxib 100 mg once daily resulted in clinically significant lower blood pressure compared with ibuprofen 600 mg three times daily in osteoarthritis patients with well controlled hypertension. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope, Luis M; Despres, Jean-Pierre; Scheen, André ULg et al

in Journal of Hypertension (2008), 26(2), 357-67

OBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis assessed ... [more ▼]

OBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with similar design - the Rimonabant-In-Obesity (RIO) programme. METHODS: RIO-Europe (n = 1507) and RIO-North America (n = 3040) recruited overweight/obese patients, and RIO-Lipids (n = 1033) and RIO-Diabetes (n = 1045) recruited overweight/obese patients with untreated dyslipidaemia or type 2 diabetes, respectively. At study entry (screening), 37.2% (n = 2463) of patients had hypertension, 71.4% (n = 1757) of whom were taking an antihypertensive treatment. RESULTS: After 1 year of treatment, mean change in systolic blood pressure (SBP) from baseline was -0.8 mmHg for rimonabant 20 mg versus +0.3 mmHg for placebo (P = 0.007); diastolic blood pressure (DBP) decreased by -0.8 versus -0.3 mmHg (P = 0.029) respectively. In the subgroup of patients with high blood pressure at baseline, SBP change was -7.5 mmHg for rimonabant 20 mg versus -4.7 mmHg for placebo (P = 0.005); DBP change was -5.2 versus -3.0 mmHg (P < 0.001). Reductions were more pronounced in patients with dyslipidaemia and type 2 diabetes. There was no effect of rimonabant 20 mg on blood pressure beyond that expected from weight loss alone. Overall, there was a similar incidence of adverse events (AEs) at 1 year in the placebo (81.8%) and rimonabant 20 mg (86.0%). The most common AEs occurring with rimonabant were nausea, dizziness, arthralgia and diarrhoea. A slightly higher proportion of patients in the rimonabant 20 mg group discontinued as a result of AEs (13.8%) versus placebo (7.2%). CONCLUSIONS: Rimonabant 20 mg led to modest, but significant SBP and DBP reductions in overweight/obese patients. The effect of rimonabant on blood pressure appears to be mediated by weight loss. [less ▲]

Detailed reference viewed: 70 (1 ULg)
Full Text
Peer Reviewed
See detailSystolic hypertension in young adults: spurious definition of a genuine condition - Reply
Krzesinski, Jean-Marie ULg; Saint-Remy, Annie ULg

in Journal of Hypertension (2006), 24(11), 2318-2319

Detailed reference viewed: 75 (5 ULg)
Full Text
Peer Reviewed
See detailAnkle-brachial blood pressure index and cardiovascular risk in hemodialized patients
Saint-Remy, Annie ULg; Sumaili, Ernest; Xhignesse, Patricia ULg et al

in Journal of Hypertension (2006, June 12), 24(suppl 4), 167

Detailed reference viewed: 18 (8 ULg)
Full Text
Peer Reviewed
See detailSpurious systolic hypertension in youth: what does it really mean in clinical practice?
Krzesinski, Jean-Marie ULg; Saint-Remy, Annie ULg

in Journal of Hypertension (2006), 24(6), 999-1001

Detailed reference viewed: 138 (4 ULg)
Full Text
Peer Reviewed
See detailEquivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
Marre, Michel; Garcia Puig, Juan; Kokot, Franciszek et al

in Journal of Hypertension (2004), 22(8), 1613-1622

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti ... [more ▼]

Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti hypertensive drugs with opposite effects on the renin-angiotensin system [the diuretic, indapamide sustained release (SR), and an angiotensin-converting enzyme inhibitor, enalapril] in reducing microalbuminuria. Design A multinational, multicentre, controlled, double-blind, double-dummy, randomized, two-parallel-groups study over 1 year. Methods After a 4-week placebo run-in period, 570 patients (ages 60.0 +/- 9.9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 mu g/min) were allocated randomly to groups to receive indapamide SR 1.5 mg (n = 284) or enalapril 10 mg (n = 286) once a day. Amlodipine, atenolol, or both were added, if necessary, to achieve the target blood pressure of 140/85 mmHg. Results There was a significant reduction in the urinary albumin: creatinine ratio. Mean reductions were 35% [95% confidence interval (Cl) 24 to 43] and 39% (95% Cl 30 to 47%) in the indapamide SR and enalapril groups, respectively. Equivalence was demonstrated between the two groups [1.08 (95% Cl 0.89 to 1.31%); P = 0.01]. The reductions in mean arterial pressure (MAP) were 16.6 +/- 9.0 mmHg for the indapamide SR group and 15.0 +/- 9.1 mmHg for the enalapril group (NS); the reduction in SBP was significantly greater (P = 0.0245) with indapamide SR. More than 50% of patients in each group required additional antihypertensive therapy, with no differences between groups. Both treatments were well tolerated. Conclusions lndapamide-SR-based therapy is equivalent to enalapril-based therapy in reducing microalbuminuria with effective blood pressure reduction in patients with hypertension and type 2 diabetes. [less ▲]

Detailed reference viewed: 46 (0 ULg)
Full Text
Peer Reviewed
See detailPrevalence of microalbuminuria in hypertensive patients: A Belgian promise survey
Krzesinski, Jean-Marie ULg; Lins, R. L.; Melsens, J. et al

in Journal of Hypertension (2003, June), 21(Suppl. 4), 71

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of moxonidine on heart rates in hypertensive patients: A large scale surveillance study
Labaki, L.; Lins, R. L.; Van der Niepen, P. et al

in Journal of Hypertension (2003, June), 21(Suppl. 4), 325

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of candesartan cilexetil and angiotensin-converting enzyme inhibitor therapy on treatment adherence in hypertension
Krzesinski, Jean-Marie ULg; Lins, R.; Vandenhoven, G. et al

in Journal of Hypertension (2001), 19

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailInfluence of salt restriction in untreated essential hypertension patients
Krzesinski, Jean-Marie ULg; Du, F.; Pequeux, L. et al

in Journal of Hypertension (1992), 10(10), 1297-1298

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPredictive value and rate of change of blood pressure throughout adolescence : a Belgian prospective study
Saint-Remy, Annie ULg; Rorive, Georges ULg

in Journal of Hypertension (1991), 9(suppl 6), 266-267

We performed a prospective study on the natural course of blood pressure throughout adolescence. The major goals were to assess the predictive value of a high blood pressure level at the age of 12 years ... [more ▼]

We performed a prospective study on the natural course of blood pressure throughout adolescence. The major goals were to assess the predictive value of a high blood pressure level at the age of 12 years and the feasibilty of developing a screening test for the early detection of young subjects at risk of developing chronic hypertension. By measuring the relationship between the initial level and subsequent changes in blood pressure, we looked for a phenomenon previously demonstrated in adults. [less ▲]

Detailed reference viewed: 15 (4 ULg)